

In the claims:

Please amend the claims as follows:

1. ~~32~~ (Once amended) An isolated protein selected from the group consisting of:

B<sup>1</sup> (a) an isolated protein of at least about 20 amino acids in length, wherein said 20 amino acids are encoded by a nucleic acid molecule that has an at least 60 contiguous nucleotide region identical in sequence to a 60 contiguous nucleotide region of a nucleic acid sequence selected from the group consisting of SEQ ID NO:88, SEQ ID NO:89, SEQ ID NO:90, SEQ ID NO:91, SEQ ID NO:94, SEQ ID NO:96, SEQ ID NO:99, SEQ ID NO:102, and SEQ ID NO:104; and

(b) an isolated protein of at least about 20 amino acids in length, wherein said protein has an at least 20 contiguous amino acid region identical in sequence to a 20 contiguous amino acid region selected from the group consisting of SEQ ID NO:92, SEQ ID NO:97, SEQ ID NO:100, and SEQ ID NO:105,

wherein said isolated protein of (a) or (b) elicits an immune response against a canine IL-13 protein or has IL-13 activity.

2. ~~34~~ (Once amended) The isolated protein of Claim ~~33~~<sup>1</sup>, wherein said protein has an amino acid sequence selected from the group consisting of SEQ ID NO:92, SEQ ID NO:97, SEQ ID NO:100, and SEQ ID NO:105.

35. (Reiterated) The isolated protein of Claim 34, wherein the protein has the amino acid sequence of SEQ ID NO:92.

36. (Reiterated) The isolated protein of Claim 34, wherein the protein has the amino acid sequence of SEQ ID NO:97.

37. (Reiterated) The isolated protein of Claim 34, wherein the protein has the amino acid sequence of SEQ ID NO:100.

38. (Reiterated) The isolated protein of Claim 34, wherein the protein has the amino-acid sequence of SEQ ID NO:105.

B2 39. (Once amended) An isolated protein having an amino acid sequence that is at least about 85 percent identical to an amino acid sequence selected from the group consisting of SEQ ID NO:92, SEQ ID NO:97, SEQ ID NO:100, and SEQ ID NO:105, wherein said isolated protein elicits an immune response against a canine IL-13 protein or has IL-13 activity.

8.  
40. (Once amended) A therapeutic composition comprising the isolated protein of Claim 33.

41. (Reiterated) The composition of Claim 40, wherein said composition further comprises a component selected from the group consisting of an excipient, an adjuvant and a carrier.

42. (Reiterated) A method to regulate an immune response in an animal comprising administering to the animal the therapeutic composition of Claim 40.

B3 43. (Once amended) The method of Claim 42, wherein said animal is a canid.

44. (Reiterated) The method of Claim 42, wherein said composition further comprises a component selected from the group consisting of an excipient, an adjuvant and a carrier.

#### REMARKS

Applicants wish to thank the Examiner for discussing the application with Theresa Brown during the telephone conversation on April 3, 2002. In light of the discussion, Applicants

300

B